Diarrhea-predominant Irritable Bowel Syndrome (IBS-D), the most common form of IBS in the U.S., is a chronic and debilitating illness characterized by recurrent abdominal pain or discomfort associated with altered bowel function. The etiology of IBS is not fully understood and its underlying cause remains unknown. It can significantly impact patient quality of life physically, emotionally, socially and economically.
RHB-102 (BEKINDA®) is a once-daily, 24-hr, bimodal release, oral tablet formulation of the antiemetic drug ondansetron, a 5-HT3 antagonist.
RHB-102 (12 mg) successfully met the primary endpoint of improvement of stool consistency response (per FDA guidance definition) in a U.S. Phase 2 study in IBS-D.
Read more about the study results here.